| SECTOR | INDUSTRY |
| Health Care | Life Sciences Tools & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Cynthia McLaughlin
Tudor Pop
Tudor Pop
Cynthia McLaughlin
Cynthia McLaughlin
| Share Statistics | ADPT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3,846.1 | $1,774.7 | 63% |
|
| Shares Out (Mil) | 155.5 | 94.8 | 72% |
|
| Institutional Ownership | 96.8% | 90.1% | 71% |
|
| Float (Mil) | 124.8 | 69.9 | 66% |
|
| Beta | 2.15 | 1.20 | 94% |
|
| Avg Daily Volume (000s) | 2,936 | 838 | 87% |
|
| Price Change (52-week) |
132.7% | 81.0% | 95% |
|
| Growth | ADPT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 23.0% | 7.8% | 84% |
|
| Net Income (5yr) | 16.5% | (13.7%) | 66% |
|
| EPS (5yr) | 18.9% | 0.7% | 66 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (5.6%) | (15.0%) | 61% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 4 | 7 | |
| Current EPS | ($0.098) | ($0.542) | ($0.219) | |
| Month Ago EPS | ($0.113) | ($0.457) | ($0.253) | |
| # Rev Up | 0 | 2 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.110) | ($0.480) | ($0.269) | |
| Year/Year Chg | (24.0%) | 38.3% | (108.4%) | |
| Financials | ADPT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $295 | $763 | 36% |
|
| Net Income (TTM) (Mil) | ($50) | ($14) | 16% |
|
| EPS (TTM) | ($0.324) | ($0.200) | 31% |
|
| Operating Cash Flow (TTM) (Mil) | ($27) | $53 | 13% |
|
| Net Cash Flow (TTM) (Mil) | $27 | ($5) | 65% |
|
| Long-Term Debt (Q1) (Mil) | $194 | $270 | 50% |
|
| Enterprise Value (Q1) (Mil) | $2,735 | $2,430 | 53% |
|
| Valuation | ADPT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 17.91 | 3.00 | 95% |
|
| P/E | na | 43.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 5.3 | na |
|
| Ratios | ADPT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 43.7% | 47.6% | 54% |
|
| Net Margin | (16.8%) | (2.9%) | 18% |
|
| ROA | (9.8%) | (3.2%) | 26% |
|
| ROE | (24.4%) | (4.5%) | 22% |
|
| Liabilities to Assets | 55.7% | 43.0% | 48% |
|
| F-Score | 5 | 5 | 51% |
|
Adaptive Biotechnologies Corporation did not pass any screens on 7/30/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors
